Journal of Capital Medical University ›› 2015, Vol. 36 ›› Issue (4): 519-524.doi: 10.3969/j.issn.1006-7795.2015.04.001

Previous Articles     Next Articles

MicroRNA and non-small cell lung cancer

Tan Xiaogang, Zhi Xiuyi   

  1. Department of Thoracic Surgery, Xuanwu Hospital, Diagnostic and Treatment Centers of Lung Cancer, Capital Medical University, Beijing 100053, China
  • Received:2015-05-28 Online:2015-08-21 Published:2015-07-17
  • Supported by:

    This study was supported by National Natural Science Foundation of China(81101773); Major Project of Beijing Municipal Science and Technology Commission(D14110700020000); Capital Medical University Foundation-clinical Research Cooperation Fund(14JL25).

Abstract:

Lung cancer has the highest world-wide cancer mortality. Current therapies for non-small cell lung cancer(NSCLC) patients are inefficient due to the lack of diagnostic and therapeutic markers. MicroRNAs(miRNAs) are a species of small non-coding single-stranded RNA of about 21 nucleotides that through partial sequence homology may interact with the 3'-untranslated region of target mRNA molecules. Recent evidence has shown that miRNA may function as tumor supressors or oncogenes, and alterations in miRNA expression may play a critical role in the initiation and progression of lung cancer. miRNAs are not only stable in paraffin embedded tissues and body fluids, but also in plasma and serum, which makes circulating miRNA a new kind of ideal biomarker that opens a new field for early molecular diagnosis of lung cancer, as well as for prediction of lung cancer survival and therapy.

Key words: microRNA, circulating miRNA, lung cancer, diagnosis, prognosis, therapy

CLC Number: